We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Abbisko

News List

Abbisko Therapeutics and Lilly partner to develop new molecules Pharmaceutical-Technology
January 19, 2022
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules prnasia
January 18, 2022
Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's Disease and Discovery Expertise. Abbisko Therapeutics Is Eligible to Receive Research, Development and Commercial Milestone Payments.
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China prnasia
July 05, 2021
Sperogenix (Shanghai) MedTech Co., Ltd., a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications in China), has entered into an exclusive licensing agreement with Abbisko ...